Institute for Cellular Therapeutics, University of Louisville, 570 S Preston St., Louisville, KY 40202, USA.
Blood. 2011 Feb 24;117(8):2494-505. doi: 10.1182/blood-2010-06-291187. Epub 2010 Dec 29.
CD8-positive/T-cell receptor-negative (CD8(+)/TCR(-)) graft facilitating cells (FCs) are a novel cell population in bone marrow that potently enhance engraftment of hemopoietic stem cells (HSCs). Previously, we showed that the CD11c(+)/B220(+)/CD11b(-) plasmacytoid-precursor dendritic cell (p-preDC) FC subpopulation plays a critical but nonredundant role in facilitation. In the present study, we investigated the mechanism of FC function. We report that FCs induce antigen-specific CD4(+)/CD25(+)/FoxP3(+) regulatory T cells (Tregs) in vivo. The majority of chimeric Tregs were recipient derived. Chimeric Tregs harvested at ≥ 4 weeks after transplantation significantly enhanced engraftment of donor- and recipient-derived HSCs, but not third-party HSCs, in conditioned secondary recipients, demonstrating antigen specificity. Although Tregs were present 2 and 3 weeks after transplantation, they did not enhance engraftment. In contrast, week 5 and greater Tregs potently enhanced engraftment. The function of chimeric Tregs was directly correlated with the development of FoxP3 expression. Chimeric Tregs also induced significantly stronger suppression of T-cell proliferation to donor antigen in vitro. Removal of p-preDC FCs resulted in impaired engraftment of allogeneic HSCs and failure to produce chimeric Tregs, suggesting that the CD8α(+) p-preDC subpopulation is critical in the mechanism of facilitation. These data suggest that FCs induce the production of antigen-specific Tregs in vivo, which potently enhance engraftment of allogeneic HSCs. FCs hold clinical potential because of their ability to remain tolerogenic in vivo.
CD8阳性/T 细胞受体阴性(CD8(+)/TCR(-)))移植物促进细胞(FCs)是骨髓中一种新型细胞群体,能够有力地增强造血干细胞(HSCs)的植入。先前,我们表明 CD11c(+)/B220(+)/CD11b(-)浆细胞样前体树突状细胞(p-preDC)FC 亚群在促进作用中发挥关键但非冗余的作用。在本研究中,我们研究了 FC 功能的机制。我们报告 FCs 在体内诱导抗原特异性 CD4(+)/CD25(+)/FoxP3(+)调节性 T 细胞(Tregs)。嵌合 Tregs 的大多数是受体衍生的。在移植后≥4 周收获的嵌合 Tregs 显著增强了条件性二级受体中供体和受体来源的 HSCs 的植入,但不能增强第三方 HSCs 的植入,证明了抗原特异性。尽管 Tregs 在移植后 2 周和 3 周存在,但它们不能增强植入。相比之下,第 5 周及以后的 Tregs 能够有力地增强植入。嵌合 Tregs 的功能与 FoxP3 表达的发展直接相关。嵌合 Tregs 还显著增强了对供体抗原的 T 细胞增殖的抑制作用。去除 p-preDC FCs 导致同种异体 HSCs 植入受损且不能产生嵌合 Tregs,表明 CD8α(+)p-preDC 亚群在促进作用的机制中至关重要。这些数据表明,FCs 在体内诱导抗原特异性 Tregs 的产生,从而有力地增强同种异体 HSCs 的植入。由于 FCs 具有在体内保持耐受原性的能力,因此它们具有临床潜力。